CAN-2409

· Candel Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for CAN-2409, covering 2024-01-08 to 2025-08-22. Get the full timeline:

Most recent: Clinical Trial Update: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC [Phase 2]